Background
Phase III, double-blind, placebo-controlled RCT. 1836 patients with HER2-negative (HR+ or TNBC) early breast cancer with germline BRCA1 or BRCA2 pathogenic variants at high risk of recurrence (prior NACT or adjuvant chemotherapy required; ≥6 months of platinum-based chemo counted). Olaparib is a PARP inhibitor; BRCA1/2 deficiency creates synthetic lethality with PARP inhibition. ~84% of enrolled patients had TNBC.
Interventions and follow up
Arm A: Olaparib 300mg BID × 1 year (after completing standard (neo)adjuvant chemotherapy)
Arm B: Placebo BID × 1 year
Primary endpoint: Invasive disease-free survival (IDFS)
mFollow up: 4.5 years (OS analysis)
Arm B: Placebo BID × 1 year
Primary endpoint: Invasive disease-free survival (IDFS)
mFollow up: 4.5 years (OS analysis)
Results
IDFS (3-yr): 85.9% vs 77.1%, HR 0.58, 95% CI 0.41–0.82, P<.001
OS (4-yr): 87.5% vs 83.4%, HR 0.68, 95% CI 0.47–0.97, P=.009
DRFI (3-yr): 87.5% vs 80.4%, HR 0.57
OS (4-yr): 87.5% vs 83.4%, HR 0.68, 95% CI 0.47–0.97, P=.009
DRFI (3-yr): 87.5% vs 80.4%, HR 0.57
Adverse events
Hematologic: Grade ≥3 anemia 8.7% vs 1.3%; MDS/AML 0.2% vs 0.0%.
GI/constitutional: Grade ≥3 nausea 0.4% vs 0.1%; grade ≥3 fatigue 1.8% vs 0.9%.
Dose management: Dose reduction 23.2%; discontinuation 10.8%; overall well-tolerated with PARP-inhibitor class-typical toxicities.
GI/constitutional: Grade ≥3 nausea 0.4% vs 0.1%; grade ≥3 fatigue 1.8% vs 0.9%.
Dose management: Dose reduction 23.2%; discontinuation 10.8%; overall well-tolerated with PARP-inhibitor class-typical toxicities.
Conclusions
Adjuvant olaparib for 1 year significantly improved IDFS and OS in gBRCA-mutated HER2-negative early breast cancer patients who had completed standard chemotherapy. OlympiA is the first trial to demonstrate both IDFS and OS benefit for a PARP inhibitor in the adjuvant setting.
Key Limitations
Benefit requires germline BRCA1/2 testing — somatic BRCA mutations were not included and have uncertain implications. Roughly 84% TNBC enrollment means results in the HR+/HER2- subgroup are less robustly powered. MDS/AML risk is low but requires monitoring, particularly in older patients with prior alkylating agent exposure. Optimal sequencing with KEYNOTE-522 pembrolizumab in TNBC (can both be given?) is not established by prospective data. Patients with prior platinum-based therapy (e.g., carboplatin in KEYNOTE-522) may have a different response profile.
Clinical Context
OlympiA established adjuvant olaparib as standard of care for gBRCA-mutated HER2-negative early BC at high recurrence risk (FDA approved 2022; ESMO-MCBS score: 5). BRCA1/2 germline testing is recommended for all TNBC and high-risk HR+ patients per ESMO/ASCO guidelines. Olaparib is the first PARP inhibitor approved in the adjuvant solid tumor setting. Its use with or after pembrolizumab-based neoadjuvant regimens requires ongoing clinical guidance.